Wiley Bros. Aintree Capital, LLC Abb Vie Inc. Transaction History
Wiley Bros. Aintree Capital, LLC
- $2.26 Billion
- Q2 2024
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 38,958 shares of ABBV stock, worth $7.93 Million. This represents 0.3% of its overall portfolio holdings.
Number of Shares
38,958
Previous 14,788
163.44%
Holding current value
$7.93 Million
Previous $2.69 Million
148.22%
% of portfolio
0.3%
Previous 0.37%
Shares
19 transactions
Others Institutions Holding ABBV
# of Institutions
3,771Shares Held
1.28BCall Options Held
13MPut Options Held
9.83M-
Vanguard Group Inc Valley Forge, PA171MShares$34.7 Billion0.57% of portfolio
-
Black Rock Inc. New York, NY136MShares$27.8 Billion0.54% of portfolio
-
State Street Corp Boston, MA77.8MShares$15.8 Billion0.59% of portfolio
-
Jpmorgan Chase & CO New York, NY53.6MShares$10.9 Billion0.81% of portfolio
-
Capital International Investors Los Angeles, CA38.6MShares$7.86 Billion1.4% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $360B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...